Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent Pharmaceuticals (Sagent) has launched Pamidronate disodium injection in single-dose vials, containing 30mg per 10ml and 90mg per 10ml. Pamidronate disodium injection, the generic alternative of Novartis' Aredia, is a bone resorption inhibitor.
Subscribe to our email newsletter
Pamidronate disodium is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with Pamidronate disodium.
Secondly, Pamidronate disodium is also indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Additionally, it is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.
Jeffrey Yordon, founder, chairman and CEO of Sagent, said: “Pamidronate is an important adjunctive therapy for cancer patients for the treatment of chemotherapy-associated osteoporosis. It will be a valuable addition to Sagent’s oncolytic and supportive care product line, and we believe we are well positioned to serve this market.”